XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.9036
-0.0174 (-1.89%)
At close: Apr 4, 2025, 4:00 PM
0.9500
+0.0464 (5.14%)
After-hours: Apr 4, 2025, 5:51 PM EDT

XORTX Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Jan '22 Dec '20 2015 - 2019
Net Income
-3.31-2.16-7.72-1.58-1.28
Upgrade
Depreciation & Amortization
0.120.140.060.010.02
Upgrade
Asset Writedown & Restructuring Costs
----0.06
Upgrade
Stock-Based Compensation
0.120.120.490.460.29
Upgrade
Other Operating Activities
-0.72-3.66-2.47-2.61-0.18
Upgrade
Change in Accounts Receivable
0.040.02-0.04-0.03-
Upgrade
Change in Accounts Payable
-0.13-1.190.89-0.260.41
Upgrade
Change in Other Net Operating Assets
0.210.140.62-0.79-0.04
Upgrade
Operating Cash Flow
-3.68-6.58-8.17-4.8-0.73
Upgrade
Capital Expenditures
--0-0.02--
Upgrade
Sale (Purchase) of Intangibles
-0.04-0.04-0.03-0.03-0.01
Upgrade
Investing Cash Flow
-0.04-0.05-0.05-0.03-0.01
Upgrade
Long-Term Debt Repaid
-0.07-0.07-0.02--
Upgrade
Net Debt Issued (Repaid)
-0.07-0.07-0.02--
Upgrade
Issuance of Common Stock
3.520520.070.9
Upgrade
Other Financing Activities
-0.67-0.3-1.07-0.7-0.04
Upgrade
Financing Cash Flow
2.78-0.363.9119.370.86
Upgrade
Foreign Exchange Rate Adjustments
-0.040-0.140.2-
Upgrade
Net Cash Flow
-0.97-6.99-4.4414.740.11
Upgrade
Free Cash Flow
-3.68-6.59-8.19-4.8-0.73
Upgrade
Free Cash Flow Per Share
-1.28-3.32-5.53-4.39-0.98
Upgrade
Levered Free Cash Flow
-1.11-3.67-3.8-0.83-1.74
Upgrade
Unlevered Free Cash Flow
-1.11-3.67-3.8-0.82-1.73
Upgrade
Change in Net Working Capital
-0.320.79-1.47-0.181.34
Upgrade
Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q